KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Restoring TADS: RIAT reanalysis of the Treatment for Adolescents with Depression Study.

Natalie Aboustate, Jon Jureidini, Richard Woodman, Joanna Le Noury, Julie Klau, Elia Abi-Jaoude, Melissa Raven

Int J Risk Saf Med 36(4) 218-237

PMID40421808
PMCIDPMC12552760
DOI10.1177/09246479251337879
发表日期2025-05-27
入排依据:未发现恶性肿瘤人群证据。
已检查 1 张 PubMed Figure,均未识别为 KM 图:Figure 1:AI 判定为 flow diagram。
摘要

摘要

BackgroundThe Treatment for Adolescents with Depression Study (TADS) continues to influence international clinical practice guidelines for adolescent depression.ObjectiveWe assessed TADS' effectiveness and harms through a Restoring Invisible and Abandoned Trials (RIAT)-led reanalysis.MethodsTADS was a phase-three multicentre, parallel four-arm randomised controlled superiority trial that randomised adolescents (n = 439) to fluoxetine alone (FLX), CBT alone (CBT), open-label fluoxetine plus CBT (COMB) or placebo pill alone (PBO) over 12 weeks. COMB and CBT groups were unblinded to their treatment allocation. Primary outcomes were the Children's Depression Rating Scale-Revised (CDRS-R) and Clinical Global Impression-Improvement scale (CGI-I).ResultsOur ITT reanalysis showed a significant decrease in CDRS-R at 12 weeks in COMB compared with PBO (-6.65; p < 0.001) and CBT (-7.63, p < 0.001), but not FLX (-4.07, p = 0.063). There was no difference between FLX, CBT and PBO. There was a higher proportion of CGI-I responders in COMB (73.72% [SE 4.43]) compared with all other arms: FLX (64.16% [SE 4.76]), CBT (51.06% [SE 5.29]) and PBO (38.76% [SE 4.87]; all p < 0.001); FLX had more responders than PBO (p = 0.004). 369 adverse events were reported for 171 participants, with 66% occurring in those taking fluoxetine. We found 32 serious adverse events (22 in those taking fluoxetine), which varied from original authors' reporting.ConclusionsOur reanalysis replicated the original investigators' reporting that COMB demonstrated the most robust outcomes and that FLX was not superior to PBO. In contrast to the original TADS Team's reporting, there was a higher level of harm uncovered in allocation groups taking fluoxetine, including 11 unreported suicide-related adverse events. Overall, the marked increase in harms among participants taking fluoxetine warrants further circumspection when prescribing it to adolescents.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(1,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1. Flowchart of participants by treatment arm. Counts reflect data available for the CDRS-R, where ITT = intention-to-treat population, OC = observed cases, and PP = per protocol population (participants who did not drop out, were not prematurely terminated and had a week-12 CDRS-R rating). Drop out and premature termination may have occurred in the same participant and are not mutually exclusive in this figure.
非 KM Figure